Evidence map›Paper›PMID 37894438›Full record

ArticleCancers2023

Compromised Blood-Brain Barrier Junctions Enhance Melanoma Cell Intercalation and Extravasation.

Federico Saltarin, Adrian Wegmüller, Leire Bejarano, Ece Su Ildiz, Pascale Zwicky, Andréj Vianin, Florentin Spadin, Klara Soukup, Vladimir Wischnewski, Britta Engelhardt and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. A Review on Melanoma Brain Metastases.Current pharmaceutical design · 2026
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Federico SaltarinTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.
Adrian WegmüllerTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.ORCID 0009-0003-1203-2990
Leire BejaranoDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Ece Su IldizTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.
Pascale ZwickyTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0003-0419-2153
Andréj VianinDepartment of Developmental Biology and Regeneration, Institute of Anatomy, University of Bern, 3012 Bern, Switzerland.
Florentin SpadinInstitute of Applied Physics, University of Bern, 3012 Bern, Switzerland.
Klara SoukupDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-2764-4845
Vladimir WischnewskiDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Britta EngelhardtTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.
Urban DeutschTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.
Ines J MarquesDepartment of Developmental Biology and Regeneration, Institute of Anatomy, University of Bern, 3012 Bern, Switzerland.
Martin FrenzInstitute of Applied Physics, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-6741-9434
Johanna A JoyceDepartment of Oncology, University of Lausanne, 1011 Lausanne, Switzerland.
Ruth LyckTheodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-6479-4837
University of Bern · CHLudwig Cancer Research · CH

Funding

Austrian Science Fund FWF J 4343Berne University Research Foundation n/aFoundation for Clinical-Experimental Cancer Research n/aHuman Frontier Science Program postdoctoral fellowship n/aLudwig Foundation for Cancer Research and the University of Lausanne n/aRuth & Arthur Scherbarth Stiftung n/a
6 · The paper itself

Abstract

Melanoma frequently metastasises to the brain, and a detailed understanding of the molecular and cellular mechanisms underlying melanoma cell extravasation across the blood-brain barrier (BBB) is important for preventing brain metastasis formation. Making use of primary mouse brain microvascular endothelial cells (pMBMECs) as an in vitro BBB model, we imaged the interaction of melanoma cells into pMBMEC monolayers. We observed exclusive junctional intercalation of melanoma cells and confirmed that melanoma-induced pMBMEC barrier disruption can be rescued by protease inhibition. Interleukin (IL)-1β stimulated pMBMECs or PECAM-1-knockout (-ko) pMBMECs were employed to model compromised BBB barrier properties in vitro and to determine increased melanoma cell intercalation compared to pMBMECs with intact junctions. The newly generated brain-homing melanoma cell line YUMM1.1-BrM4 was used to reveal increased in vivo extravasation of melanoma cells across the BBB of barrier-compromised PECAM-1-deficient mice compared to controls. Taken together, our data indicate that preserving BBB integrity is an important measure to limit the formation of melanoma-brain metastasis.

Indexed as

blood-brain barrier (BBB)cell extravasationendothelial junctionsmelanomametastasis

Identifiers

PMID37894438
PMCPMC10605101
OpenAlexW4387821924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.